January 2019
Washington, D.C. (Jan. 22, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, announced that Commerce Secretary Wilbur Ross will be testifying before the Oversight Committee on March 14, 2019:
| Washington, D.C. (Jan. 22, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, issued the following statement after House Speaker Nancy Pelosi announced the new Members of the Committee: |
Washington, D.C. (Jan. 19, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, Rep. Jerrold Nadler, the Chairman of the Committee on the Judiciary, and Rep. Bennie G.
| Washington, D.C. (Jan. 17, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, issued the following statement in response to a new report from the Department of Health and Human Services (HHS) Inspector General on the Trump Administration's immigrant child separation policy: |
| Washington, D.C. (Jan. 16, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, issued the following statement in response to a scathing new report from the General Services Administration (GSA) Inspector General (IG) on the Old Post Office lease with President Trump's company: |
| Washington, D.C. (Jan. 15, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, issued the following statement after the House of Representatives passed five bills on a bipartisan basis sponsored by Members of the Oversight Committee: |
| Washington, D.C. (Jan. 15, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, issued the following statement after a U.S. District Court Judge ruled against the Trump Administration's plan to add a citizenship question to the 2020 Census and concluded that Commerce Secretary Wilbur Ross violated federal law: |
Washington, D.C. (Jan. 14, 2019)—Today, Rep. Elijah E. Cummings, the Chairman of the Committee on Oversight and Reform, launched one of the most wide-ranging investigations in decades into the prescription drug industry's pricing practices.